Nicolas Beuzen

Business Development Director. Nicolas has over 15 years’ experience working for various biopharmaceutical companies in France, India and Poland, from large and mid-size pharma, to start-ups. In his different roles including chief scientific officer and business development director, he has gained broad and applied knowledge in the development of new chemical entities (NCEs) and biologics for neurodegenerative diseases, oncology and rare diseases. Working with high performance, international R&D teams, he obtained experience in evaluation, negotiation and management of strategic alliances and partnerships. Nicolas is co-inventor on 2 patents. He holds a PhD in molecular biology and genomics from the University of Glasgow and a master in management and administration from the Université Lyon III in France.


Paweł Bochniarz

Pawel is a serial entrepreneur, advisor, mentor, and expert in commercialization of new technologies.

Pawel’s current role is Chairman of MIT Enterprise Forum Poland. MIT Enterprise Forum (MITEF) is a global organization of dedicated professionals with local chapters, affiliated with the Massachusetts Institute of Technology (MIT). MIT EF helps early-stage technology entrepreneurs succeed faster through relevant and practical programming and content to help them tackle real-world challenges.

Previously Pawel worked i.a. as the Innovation Advisory Director at PwC. In this capacity Pawel co-operated with public research institutions and technology startups in Poland to help commercialize their IP. In the years 2008-2010 Pawel also was a Member of the Advisory Board of the Prime Minister of Poland, co-ordinating preparations of the first Report on the National Intellectual Capital of Poland.

Pawel is also a Partner at ValueTech – a seed-stage venture capital fund and sits on investment boards of two university gap funds in Poland.

Pawel is a co-founder of Coalition For Polish Innovations – a public-private partnership established in 2015 to develop the Polish innovation Ecosystem

Pawel is an alumnus of Economics studies at the University of Warsaw. He also completed the Advanced Management Program at IESE Business School. Expert and Adviser experienced within the field of startups creation and acceleration.


Michael Dembinski

Michael Dembinski was born in London in 1957. Educated at Warwick University and The City University, he worked for 16 years at the Confederation of British Industry, nine years as managing editor of its monthly magazine, CBI News. In 1997, Michael moved to Poland with his young family to take up the position of director of communications at Polska Telewizja Kablowa (now UPC Polska). In 1999, Michael became managing director of classified advertising publisher Trader.com Polska (now a part of Agora S.A.). Since 2002, he has been working with the British Polish Chamber of Commerce, where he is chief advisor.‎


Maciek Drozdz

Principal, Venture Investments.

Maciek Drozdz is a Principal of Venture Investments for Johnson and Johnson Development Corporation (JJDC) and joined in 2017. Maciek is based in London at the Johnson and Johnson Innovation Centre.

Maciek has spent 10 years working in the Venture Capital and biotech industry. Most recently he served as a CEO of Antagonis Biotherapeutics, an immuno-oncology company in Graz, Austria. Previously he was investment manager at Entrepreneurs Fund LLP, investment director at MCI Bioventures and an analyst at Atlas Venture. Maciek has served on a number of boards of private and public companies across several countries.

Maciek received his Master’s Degree in molecular biology from the Adam Mickiewicz University in Poznan, Poland followed by a Doctorate at the University of Heidelberg in Germany. He has also worked as a Postdoc at the Friedrich Miescher Institute in Basel, Switzerland. Maciek holds an MBA degree from the Said Business School in Oxford. He lectured a course in “Innovation in Biotechnology” at Adam Mickiewicz University.


Peter Dudek

Peter joined Wellington Partners in February 2016 as a Principal. Prior to joining Wellington, Peter was an Investment Associate at Entrepreneurs Fund, a London-based pan-European venture fund with more than $200m of assets under management. Peter served as a Board Observer on Vasopharm and Optinose, and supported multiple transactions across the life sciences portfolio including investments in Vasopharm, Optinose, Cytoo, Sequana Medical and Prosonix, as well as Prosonix’s sale to Circassia.

Before EF, Peter consulted for a number of European venture-backed biotechnology startups and was an interned Analyst at Novartis Venture Funds. In his prior life as a scientist, Peter worked in the field of ncRNAs and chromatin remodelling as a Research Fellow at the University of Oxford (Queen’s), obtained his PhD from the University of Geneva in oncology, and a BSc (Hons) in immunology from the University of British Columbia. He also conducted research on the Hepatitis C virus at the BC Centre for Disease Control.


Jane Eisner

Jane Eisner heads European Sales and Account Management for QuintilesIMS, where she is responsible for the growth and delivery of the R&D business portfolio in Europe, including global strategic partnerships.

With more than 20 years with Quintiles, Jane has held a variety of leadership positions across sales, account management and study delivery. Building on her strong performance track record, her passion for customer service is a key attribute as she develops partnering solutions for her customers. One of Jane’s proudest achievements creating Quintiles’ “Global Access to Patients” group, which delivers patient outreach and engagement programs plus an investigator partner program that is now core to R&D Solutions study delivery.

Jane holds a Bachelor of Science degree in pharmacy from the University of Bath UK.


Jörn Erselius

Jörn Erselius is Managing Director of Max Planck Innovation (MI), the technology transfer agency of the Max Planck Society (MPG), the largest German basic research organization. He joined MI in 1991 as Patent- and Licensing Manager and was responsible for advising inventors and commercializing technology in the life science field. Later he took over responsibility for the patent and licensing department of MI. He negotiated numerous license agreements and consulted many spin offs from Max Planck Institutes, such as Evotec or Alnylam.

Jörn Erselius studied Biology at the University of Heidelberg and joined for his PHD studies the Department of Prof. Peter Gruss at the Max Planck Institute for Biophysical Chemistry in Göttingen.

In 2004 he received his “Master of Business Administration (MBA)”, main focus: Management, from the University of Applied Sciences in Deggendorf. He wrote his master thesis on the topic “Patenting biotechnological inventions in Europe and the US”.

Since 2011 he is “Registered Technology Transfer Professional, RTTP” (granted by ATTP, the Alliance of Technology Transfer Professionals).

Jörn Erselius served for four years as Vice President of ASTP (Association of European Science & Technology Transfer Professionals) and represents Max Planck Innovation and the Max Planck Society in boards of Max Planck spin offs and as expert in several national and international committees (BMBF, BMWi, European Commission, OECD).


Anna Grzelak

Anna is a partner at WTS Patent Attorneys and a Polish and European patent attorney specialising in the solutions in the areas of biotechnology, pharmacy, human and veterinary medicine and patent searches. She holds a PhD in biology.

Anna is a member of the Polish Chamber of Patent Attorneys. She speaks native Polish, fluent English and has a basic understanding of Russian. Anna graduated with MSc from the Faculty of Biology of the University of Warsaw with a specialisation in Microbiology. She performed her PhD thesis research at the Institute of Genetics of the University of Warsaw and obtained her Honours PhD in biology with a specialisation in genetics.

Anna obtained a post-graduate diploma in Industrial Property Law at the Faculty of Law and Administration of the University of Warsaw. She also underwent the attorney course offered by the Polish Chamber of Patent Attorneys. She is a Polish patent attorney, and is also licensed to represent clients before the Office for the Harmonisation of the Internal Market (OHIM) in matters relating to community trademarks and industrial designs.

Prior to joining WTS Patent Attorneys, she spent seven years in another large patent agency in Warsaw. As a Polish patent attorney and partner at WTS Patent Attorneys she services leading global biotechnological, pharmaceutical, veterinary and chemical companies, in matters relating to the protection of inventions. She works in Warsaw office.


Krzysztof Jakubczak

Krzysztof Jakubczak, PhD, is a graduate from the Institute of Optoelectronics of the Military University of Technology in Warsaw (MSc) and Czech Technical University in Prague (PhD). Additionally, has built his professional skills at Stanford University (USA), Laboratoire d'Optique Appliquée – LOA (France), Korean Advanced Institute of Science and Technology – KAIST (South Korea), Desy Synchrotron in Hamburg (Germany), Universidad de Salamanca (Spain) and many others.

Krzysztof’s expertise covers: medical devices, lasers, optics, infrared technology, light detection, secondary sources, lithography, vacuum systems, spectroscopic methods, and defense. Krzysztof is experienced R&D engineer and manager in the optoelectronics domain. He worked as a Deputy Project Manager at new R&D HiLASE Center in Czech Republic on innovative laser technologies for industry. He was responsible there for business development and management of a research program. Krzysztof’s commercial experience covers running engineering department at a med-tech company, building a company from a startup phase to the fully operation production facility, building and managing a number of startups developing various new technologies (med-tech, material sciences, optoelectronics). He is also an active advisory consultant in commercialization and tech-transfer fields. He worked as an Operations Director for the National Center for Research and Development where he with his team was responsible for evaluation and commercialization activities in Life Sciences field (pharma, med-tech, agro). Krzysztof cooperates with LaserLab Europe, MIT Enterprise Forum Poland, Polish Standardization Committee, investors and technological innovators.

Roland Kozłowski

Roland Kozłowski

Roland received a first class hon¬ours degree from the Uni¬ver¬sity of Bath and a PhD from the University of Cambridge. He is a serial bioentrepreneur, investor and mentor who has worked in the industry for over twenty five years. Roland was Chief Executive Officer of Lectus Therapeutics and Sense Proteomic Limited two venture capital backed companies which he founded, built and sold. During his career Roland has lead or played a key role in a many transactions including company financing, sale, purchase, financing and in and out-licensing with a cumulative value of over $200m. Earlier in his career Roland ran Research Groups at the University of Oxford and Univer¬sity of Bristol where he published and patented in the life science field. He has been a Visiting Industrial Professor, served on, or advised the boards of several European companies and organizations including the Bio-Industry Association in the UK. Presently he is President and owner of Life Science Biznes Consulting which specializes in commercializing technology from emerging economies particularly in Poland. He has acted as an advisor to the National Centre of Research & Development in Poland and the Polish Development Agency. He is a founder and limited partner in Life Science Innovations a specialist VC fund based in Poland and a director or mentor to a number of start-up companies.


Katarzyna Koziak

Dr. Katarzyna Koziak is a graduate cum laude from the Department of Embryology at the Faculty of Biology of University of Warsaw. Already as a student of Prof. Andrzej Tarkowski she joined the research team of Jacques Testart and Rene Frydman in Paris, France, where she worked on gametes maturation and clinical aspects of in vitro fertilization. After her return to Poland, dr. Koziak started to work at the Medical University of Warsaw where she in 1994 obtained her Ph.D. cum laude presenting a dissertation on erythropoietin production in kidney transplant recipients. Her scientific career continued in the United States, where she moved for a five-year postdoctoral training at Harvard Medical School. Working in Sandoz-founded Fritz Bach’s group dr. Koziak investigated endothelial cell biology and was one of the discoverers of NTPDase I, the key endothelial enzyme regulating vascular coagulation and homeostasis. Following her return to Poland, she continued research on vascular inflammation and in 2006 defended cum laude a habilitation (D.Sc.) dissertation. As an recognized and experienced researcher dr. Koziak participates as a principal investigator or co-investigator in several research projects in fields of vascular biology founded mostly by Polish Committee for Scientific Research, European Council, Polish National Science Center and Foundation of Polish Science. Dr. Katarzyna Koziak co-authored numerous research articles, text books and patent applications. She is also a recognized academic teacher, currently responsible for specialized curriculum in biochemistry for students of Medical University of Warsaw. Dr. Koziak’s achievements were recognized by Polish authorities – she received twice the award of Prime Minister of Poland.


Mateusz Kowalewski

Partner Augere Health Food Fund, investor, industry expert. Family entrepreneur in the second generation. Co-owner and CEO of HORTIMEX. Since 2009 he manages a company, a platform for the exchange of goods, knowledge and experience between global food ingredients producers and Polish food producers. Practices of modern organization and management of family business.


Olga Krylova

Olga Krylova, PhD, Senior Director, UK Global Scout, External R&D Innovations, Pfizer

Olga holds PhD in Neurobiology from Russian Academy of Medical Sciences.

From 2006 she worked for Mitsui & Co Europe, London, as Senior Researcher in Business Development supporting private equity investment and pharma-related business.

Prior to that she worked as a Principle Scientist in GlaxoSmithKline R&D, Psychiatry Centre of Excellence for Drug Discovery in the UK. In her role at GSK Olga led programs in early discovery research for schizophrenia and Bipolar Disorder.

Olga moved to the UK in 1994 to do a post-doctoral study in UCL followed a similar position in Imperial College.

At her current role in Pfizer Olga is heading Pfizer R&D Scouting efforts in the UK looking for opportunities to partner from academic research to POC clinical stage assets across all the therapeutic areas of Pfizer interest which are CVMet, Inflammation&Immunology, Neuroscience, Oncology, Rare Disease and Vaccines.

dr Gabor Lamm

Gabor Lamm

Dr. Lamm (born 1967 in Budapest) is a graduate of Edinburgh University (Biochemistry) and holds a Ph.D. in Molecular Biology. After spending three years as a research scientist at the Boehringer Ingelheim Institute of Molecular Pathology (IMP) in Vienna, Dr. Lamm joined Wacker Chemie, a major global supplier of silicone and polymer raw materials and semiconductors. At Wacker Chemie Dr. Lamm was Business-Team Leader in the division specialising in advanced ceramic components for high-tech applications. As of October 2000 he is Managing Director of EMBL Enterprise Management Technology Transfer GmbH (EMBLEM), a 100% subsidiary of the European Molecular Biology Laboratory (EMBL; http://www.embl.org). Dr. Lamm is an alumnus of the European Molecular Biology Laboratory Ph.D. program and of the Boehringer Ingelheim Fonds, on the advisory board of various associations and start-up companies, co-founder of the VC vehicle EMBL-Ventures, and former vice-president (20022006) of the Association of European Science and Technology Transfer Professionals (ASTP).

Magdalena Marciniak

Magdalena Marciniak

Magdalena holds a MSc degree in Food Science and Human Nutrition from the University of Agriculture in Krakow and BSc in Management from the same University. In years 2010-2011 she had an internship at University of Copenhagen at Life Science Department, where she was involved in several scientific and interdisciplinary projects.

Based on her previous experience Magdalena is a qualified manager with strong background in the area of FMCG, retail market and production. Magdalena joined Selvita in 2015, taking the position of Business Alliance Manager in the R&D Department, combining scientific background with excessive business management skills. Magdalena was involved in negotiating and managing partnering deals with H3 Biomedicine, Merck KGaA and Nodthera. She is also responsible for in-licensing discussion with pharma/biotech companies and investors.


Stefan Ogrodzinski

Stefan Ogrodzinski received his BSc (Hons) in Toxicology and Pharmacology from The School of Pharmacy, University College London, in 1987 and his MBA from De Montfort University in 1999. Stefan's career has spanned the pharmaceutical industry, the healthcare sector, the voluntary sector and the educational sector, giving 25 years of sales, marketing, management and directorship experience. In 2000, Stefan founded BioStatus and has led the company as its CEO. As a founding Director of BioStatus, Stefan is responsible for the overall direction and strategic management of the business. Stefan is also a Director of BioSuspensions, OncoTherics, BioCity, MediCity and Mobius. He sits on the advisory panel for the Centre for Doctoral Training in Targeted Therapeutics and Formulation Science at Nottingham University and serves as a UKTI Catalyst Ambassador.


Jarosław Oleszczuk

His professional experience includes 3 years of medical practice, 5 years of consulting career at McKinsey & Company in Warsaw and Chicago and 10 years of management in international pharmaceutical corporations (Novartis, Abbott Laboratories and AbbVie). From October 2009 till to December 2012 he was the C of the Management Board of Abbott Laboratories Poland Sp. o. o. where, among other things, he developed and implemented Solvay Pharmaceuticals business integration strategies with his parent company. At that time he was also a member of the INFARMA Supervisory Board. From January 2013 to October 2014 he was President of the Board of AbbVie Polska - he was the founder of AbbVie Polska, which was formed from the spin-off of the pharmaceutical business with Abbott Laboratories. Between October 2014 and May 2016 AbbVie was Chairman of the Board of Directors of Belgium and Luxembourg. He is the author or co-author of more than 100 publications in the world's scientific journals. He completed his medical studies at the Medical University of Lublin and his doctorate at the Institute of Mother's Health in Łódź, winning the Prime Minister's Award.

In the years 2010-2014 he was associated with INFARMA, first as a member of the Supervisory Board, then as a member of the Board and a Treasurer. In the years 2014-2016 he was also a member of the board of PHARMA.BE - Belgian and Luxembourg pharmaceutical and biotech associations, comprising more than 130 member companies.


Martin Oxley

Martin Oxley has spent his career in a fast moving emerging markets with a focus on business strategy & development. He has held top management positions in a number of Blue Chip & CEE based pharmaceutical companies. He has also been a CEO of the British Polish Chamber of Commerce (BPCC), which under his leadership was recognized as the Best British Chamber of Commerce in Europe for four consecutive years. He was Director General of UK Trade & Investment at the British Embassy in Warsaw, where he led on the delivery of the British government’s world renowned GREAT campaign in Central Europe, one of the best ever country promotion campaigns. Martin has worked with most of the leading UK based international corporations as they have developed in the CEE region. In addition to his role as International Director IORMA, Martin is Chairman of Exorigo-Upos Group and holds a number of Advisory Board positions with innovative startups. He is passionate about digital innovation.


George Rahim

George is a pharmaceutical partnering executive with seventeen years’ experience in Global Business Development and Alliance Management at Roche and GlaxoSmithKline Biologicals and prior to that, broad international experience in Medicinal Chemistry and R&D, Project and Line Management and Business Consulting in Biotechnology.

George recently joined UCB to help establish the Alliance Management Centre of Expertise and create patient value from external partnerships and is currently developing an Alliance Management Community of Practice within UCB. Before joining UCB, George was the Head of Alliance Management and Operations at GlaxoSmithKline Biologicals in Belgium. George’s professional experience spans the entire pharmaceutical value chain from discovery to commercialization related to small molecules, biologicals and vaccines and he is a recognized practitioner in alliance management with both corporate and academic partners.

George holds a PhD in Chemistry from the University of Birmingham, UK.


Radosław Rudź

Radosław Rudź, PhD. in Medical Biology also with education background in Management and Protection of Environment. Currently works in Centre for Technology Transfer CITTRU (Jagiellonian University in Krakow) as Head of Technology Transfer and Cooperation with Economy Team. Apart from management of the Team his main duties cover commercialization of life science inventions from Jagiellonian University, including drug development projects. He negotiated successfully several medicine and pharma projects which were commercialized in cooperation with Polish and foreign companies. He has also experience in Health Technology Assessment area including creation and auditing of pharmacoeconomic reports filed to Agency for Health Technology Assessment in Poland for public reimbursement of drugs.


Marcin Szumowski

Marcin Szumowski is serial entrepreneur. He received his MS and PhD degrees from the University of Illinois and earned an MBA degree in entrepreneurship and international finance. Following a successful research career in the United States, Marcin has been involved in technology transfer and start-up companies since 2000 and has co-founded and managed five start-ups, including a medical diagnostics company Medicalgorithmics S.A. (www.medicalgorithmics.com), where he was President and CEO 2005-2010. Medicalgorithmics is now traded on the Warsaw Stock Exchange with a market cap over $300M and global sales. Since 2012 he is President & CEO of OncoArendi Therapeutics S.A. (www.oncoarendi.com), a Polish innovative biopharmaceutical company dedicated to developing and commercializing novel therapeutics for neoplastic and inflammatory diseases. In four years the company has grown to almost 70 employees and over $35M research funding from private investors and public grants. Marcin is also one of co-founders and lead investors in the Life Science Innovations (LSI) early stage fund. Since 2012 Marcin has also assisted the European Commission on three independent expert panels performing the impact assessment, interim and final evaluations of the Innovative Medicines Initiative (IMI), the world’s largest public-private partnership (PPP) in pharmaceutical research. Over the last 15 years Marcin has managed over 40 R&D and investment projects with a total value well over $250M.


Irina Staatz-Granzer

Irina Staatz-Granzer, PhD, founder and owner of Staatz Business Development & Strategy has more than 20 years of business development experience in the pharmaceutical and biotechnology industry. She has successfully negotiated a broad variety of global, regional and local agreements with an aggregate deal value exceeding USD 1.7 BN. She and her team advise and support leading VC firms as well as international biotech and pharmaceutical companies in the strategy and the operations of their technology / project / product licensing, collaborations and divestment/acquisitions including M&A on the sell as well as on the buy side. Prior to her own business she held various industrial C level positions (including CEO/ VP) at Hermal (Merck KGaA), Boots Healthcare Intl, Knoll (later Abbott), Scil Technology, U3 Pharma, Blink Biomedical. She is Vice Chairman of the public Innate Pharma and Chairman of private BliNK Biomedical, both France, and Founding Member and President of the German Pharma Licensing Club.


Mark Treherne

Mark has been actively involved in the biopharmaceutical industry for 25 years and was a co-founder in 1997 and Chief Executive of Cambridge Drug Discovery, leading the Company’s acquisition by BioFocus plc, where he then became a Commercial Director, driving significant growth of its profitable services business. Mark has now served on the Boards of 15 private and public biopharmaceutical companies in Australia, France, Denmark, the Netherlands and the UK. Mark joined the Life Sciences Organisation (LSO) as Chief Executive in 2012, following its formation by‎ UK Trade & Investment‎. While at the LSO he worked with the UK Government to bring in £6 billion in inward investment, before leaving to return to the biotechnology sector in 2016. Mark is currently Chief Executive of Avilex Pharma in Copenhagen. He initially trained as a neuroscientist and electrophysiologist at Cambridge University in the 1980s.‎


Wojciech Tworzyński

Mr Tworzynski is responsible for project analysis and deeply involved in the process of soliciting projects and maintaining relationships with the scientific and start-up environment in Poland. Before JPIF, he worked for a highly specialized medical device company where he was product manager and advisor for clinical studies. Mr Tworzynski holds a degree in molecular biology (genetics and biotechnology) from Warsaw University.


Simon Wallwork

With over 28 years experience advising on acquisitions, disposals, private equity and public market transactions, for a wide variety of clients including public and private companies, banks, venture capital funds and partnerships, Simon also has considerable client side experience spending a number of years working in-house with Pilkington plc where he was involved in a number of cross border transactions.

Simon has worked in the life sciences sector for over 20 years having acted on the listing of Oxford Molecular Group plc. He has acted for many companies in the sector from incorporation through funding rounds to eventual exit by way of sale or IPO. He has a deep understanding of the sector and its key drivers.